News

HOUSTON, TEXAS (August 23, 2018) – Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the […]

Houston, TX (July 23, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. The Board of Directors tapped Dr. Fain to build upon the foundation of innovative technology established over recent

HOUSTON, TEXAS (July 10, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, announced today it has hired three additional team members to support the advancement of its intra-aortic heart pump, AortixTM, for use in NYHA Class III-IV heart failure patients. Patricia DaSilva, Margo Fendrich, and Aaron

Podimetrics today announced that the Podimetrics Remote Temperature Monitoring (RTM) System has been selected as the Bronze Winner in the Rehabilitation and Assistive Technology Products category of the 20th Annual Medical Design and Excellence Awards competition. The 2018 winning products were announced at the MDEA Ceremony held Tuesday, June 12, 2018 in conjunction with MD&M

Pipeline Inc. held its annual entrepreneurial awards gala Thursday evening, which honored several local entrepreneurs and introduced the 2018 Pipeline class members.  Evan Luxon received Innovator of the Year, which is based on three components: performance during the Pipeline fellowship year; scores from the fellows’ retooled business plans post-Pipeline modules; and scores from the pitch

Emeryville, California, August 23, 2017. Channel Medsystems, developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has secured a $14.1mm Series C-1 financing. The insider-led round included participation by Third Point Ventures, InCube Ventures, Aperture Venture Partners, Scientific Health Development, Longwood Fund, and Boston Scientific. Channel Medsystems has developed

Emeryville, California, June 26, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced today that it has earned CE Mark approval, allowing the Company to initiate marketing efforts and commercialization of its Cerene Cryotherapy Device (Cerene device) in Europe. The Cerene device is intended for endometrial cryoablation in

Emeryville, California, March 20, 2017. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the successful completion of the treatment phase in its CLARITY Pivotal Study. The goal of the CLARITY study is to evaluate the safety and effectiveness of the Cerene® Cryotherapy Device (Cerene device) in 242 women

Emeryville, California, November 14, 2016. Channel Medsystems, the developer of an innovative, physician office-based therapy for heavy menstrual bleeding, announced the treatment of the first subjects in the US phase of its CLARITY Pivotal Study. CLARITY is a multicenter study to evaluate the safety and effectiveness of the Cerene™ Cryotherapy Device for endometrial ablation in

San Francisco, California, August 31, 2015. Channel Medsystems today announced a $22 million Series C financing led by Third Point Ventures. Additional participants in the round included new investor Longwood Fund, joined by insiders Scientific Health Development, Aperture Venture Partners, InCube Ventures and Boston Scientific. Per the terms of this financing, Jason Hong, Ph.D., of